- Type / Class
- Equity / Common Stock
- Shares outstanding
- 50,868,756
- Total 13F shares
- 42,035,725
- Share change
- +448,154
- Total reported value
- $345,140,942
- Put/Call ratio
- 99%
- Price per share
- $8.21
- Number of holders
- 159
- Value change
- +$5,513,913
- Number of buys
- 84
- Number of sells
- 78
Quarterly Holders Quick Answers
What is CUSIP 75901B107?
CUSIP 75901B107 identifies RGNX - REGENXBIO Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 75901B107:
Top shareholders of RGNX - REGENXBIO Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13D/G
13F
|
Company |
9.9%
|
5,062,477
|
$43,942,300 | $0 | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.3%
from 13D/G
|
5,454,520
|
$38,999,818 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13D/G
13F
|
Company |
7.4%
|
3,698,862
|
$34,806,291 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.8%
|
3,472,988
|
$24,831,864 | — | 31 Mar 2025 | |
| Allan M. Fox |
3/4/5
|
Director |
—
mixed-class rows
|
2,965,789
mixed-class rows
|
$23,125,113 | — | 30 May 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
4.4%
|
2,185,851
|
$20,568,858 | $0 | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
4.1%
|
2,066,895
|
$14,778,304 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
2.7%
|
1,398,497
|
$9,999,254 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2.3%
|
1,147,726
|
$8,208,025 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
1,106,946
|
$7,916,481 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2%
|
1,027,536
|
$7,346,882 | — | 31 Mar 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.8%
|
925,000
|
$6,613,750 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
752,727
|
$5,381,998 | — | 31 Mar 2025 | |
| 22NW, LP |
13F
|
Company |
1.3%
|
668,679
|
$4,781,055 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.3%
|
651,943
|
$4,661,392 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
620,595
|
$4,437,255 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1.1%
|
573,173
|
$4,098,187 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.9%
|
458,538
|
$3,278,547 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.81%
|
414,067
|
$2,960,579 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.8%
|
407,120
|
$2,910,907 | — | 31 Mar 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
0.8%
|
405,281
|
$2,897,759 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.77%
|
392,795
|
$2,808,484 | — | 31 Mar 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.77%
|
390,000
|
$2,788,500 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
366,549
|
$2,620,825 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.7%
|
357,792
|
$2,558,213 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.69%
|
350,352
|
$2,505,017 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
332,829
|
$2,379,727 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.65%
|
330,891
|
$2,365,871 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.65%
|
328,966
|
$2,352,144 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.64%
|
326,708
|
$2,335,962 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.58%
|
296,800
|
$2,122,120 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.58%
|
295,000
|
$2,109,250 | — | 31 Mar 2025 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
0.53%
|
271,302
|
$1,939,809 | — | 31 Mar 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
0.51%
|
260,000
|
$1,859,000 | — | 31 Mar 2025 | |
| Olivier Danos |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
322,069
mixed-class rows
|
$1,826,628 | — | 01 Feb 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.44%
|
225,580
|
$1,612,898 | — | 31 Mar 2025 | |
| ArchPoint Investors |
13F
|
Company |
0.44%
|
221,528
|
$1,583,925 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.41%
|
206,378
|
$1,475,603 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.39%
|
199,569
|
$1,426,918 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.39%
|
197,000
|
$1,408,550 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.38%
|
195,202
|
$1,395,694 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.36%
|
183,424
|
$1,311,000 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.33%
|
168,384
|
$1,203,942 | — | 31 Mar 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.31%
|
159,383
|
$1,139,588 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.31%
|
157,266
|
$1,123,000 | — | 31 Mar 2025 | |
| Campbell & CO Investment Adviser LLC |
13F
|
Company |
0.31%
|
155,887
|
$1,114,592 | — | 31 Mar 2025 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.29%
|
149,000
|
$1,065,000 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.28%
|
141,400
|
$1,011,012 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.28%
|
140,470
|
$1,004,361 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.26%
|
131,329
|
$939,000 | — | 31 Mar 2025 |
Institutional Holders of REGENXBIO Inc. - Common Stock (RGNX) as of Q2 2025
As of 30 Jun 2025,
REGENXBIO Inc. - Common Stock (RGNX) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,035,725 shares.
The largest 10 holders included
BlackRock, Inc., Redmile Group, LLC, JPMORGAN CHASE & CO, VANGUARD GROUP INC, STATE STREET CORP, GOLDMAN SACHS GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, MORGAN STANLEY, and AQR CAPITAL MANAGEMENT LLC.
This page lists
158
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
163
Q2 2025 holders
159
Holder diff
-4
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.